TAT-11: Future Vistas in Alpha Therapy of Infectious Diseases

Ottawa, ON, Canada (UroToday.com) Although radioimmunotherapy is usually associated with cancer treatment, Dr. Dadachova pointed out potential applications in other diseases such as fungal infections, bacterial infections, and even viral infections like Human Immunodeficiency Virus (HIV). HIV is traditionally treated with a combination of anti-retroviral termed Highly Active Antiretroviral Therapy (HAART).

HAART is effective in a majority of patients by reducing the viral load to essentially undetectable levels. However, it does not kill the virus and moreover, there is increasing concern about emergent HAART-resistant strains. In vivo studies with mice infected with HIV and treated with monoclonal antibody 246D labeled with Bi213 dramatically reduced the number of HIV-infected cells compared to either unlabeled antibody or an irrelevant antibody labeled with Bi213.

In another study, Dr. Dadachova and her team showed that radiolabeled mAb2556 could penetrate the blood-brain barrier for the treatment of HIV in the brain where HAART is not effective. Blood-brain barrier penetration might even be useful in the early treatment of dementia.

Presented by: Ekaterina Dadachova, Ph.D., Sylvia Fedoruk Centre of Nuclear Innovation and Chair of Radiopharmacy and Professor, University of Saskatchewan

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada

Login